Visions, exchanges, and future projects in Seoul
Seoul became the meeting point between biotechnological innovation and international clinical vision. Elisà Plastic Surgery visited the headquarters of ExoCoBio, a company globally recognized as a leader in the research and production of plant-derived exosomes, key players in the new frontiers of regenerative medicine and advanced aesthetic treatments.
During the visit, CEO Aliberti Liberato and Dr. Elisa Bolletta were guided through the various production departments, where high-quality exosomes are developed, including those derived from the Damask rose, now exported worldwide for cutting-edge scientific and clinical applications.
A global excellence at the heart of biotechnology
ExoCoBio stands as one of the most advanced players in the international biotechnology landscape applied to exosomes. Through proprietary production processes, strict quality controls, and continuous research activity, the South Korean company has become a global benchmark in the development of innovative regenerative solutions, particularly in the field of plant-derived exosomes.
The visit provided an in-depth look into the cultivation, extraction, and purification phases of exosomes, with special focus on those derived from the Damask rose, known for their regenerative and anti-inflammatory potential.
A meeting between clinical vision and scientific innovation
“Visiting ExoCoBio in Seoul means entering the place where the future of regenerative medicine is taking shape. Engaging with a global leader in the production of plant-derived exosomes strengthens our vision: delivering real, safe, and scientifically advanced innovation to our patients,”
Aliberti Liberato, CEO, Elisà Plastic Surgery.
The meeting represented a concrete moment of dialogue between clinical expertise and scientific research, laying the groundwork for potential future collaborations and the integration of increasingly advanced technologies into regenerative medicine protocols.
“Exosomes represent one of the most promising frontiers of modern regenerative medicine. Observing ExoCoBio’s production processes firsthand, particularly those related to exosomes derived from the Damask rose, was an experience of the highest scientific and clinical value,”
Dr. Elisa Bolletta.
Looking to the future
This meeting confirms Elisà Plastic Surgery’s commitment to identifying and collaborating with global scientific and technological leaders, with the aim of offering patients increasingly advanced, safe, and results-oriented solutions.
An international dialogue focused on the future of regenerative medicine, where innovation, research, and shared vision become tangible tools in the service of health and well-being.
